Bausch Health talks $5.14 billion term loan B at Libor plus 225 bps

By Sara Rosenberg

New York, Feb. 20 – Bausch Health Americas Inc. launched on Thursday its $5.144 billion seven-year first-lien term loan B with price talk of Libor plus 225 basis points with a 0% Libor floor and an original issue discount of 99.5 to 99.75, according to a market source.

The term loan has 101 soft call protection for six months, the source said.

Barclays and Citigroup Global Markets Inc. are the bookrunners on the deal. Barclays is the administrative agent.

Cashless roll and assignments are due at noon ET on Tuesday, and new money orders are due at noon ET on Feb. 27, the source added.

Proceeds will be used with new secured debt securities and cash on hand to refinance a term loan B due June 2025 and a term loan B due November 2025, to redeem in full the company’s 6.5% senior secured notes due 2022 and 7% senior secured notes due 2024, and to pay related fees, premiums and expenses.

Bausch is a Laval, Quebec-based specialty pharmaceutical and medical device company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.